Emily Chan
Faculty Member
Last active: 3/28/2014

  1. Anal cancer: progress on combined-modality and organ preservation. Chan E, Kachnic LA, Thomas CR (2009) Curr Probl Cancer 33(5): 302-26
    › Primary publication · 20082844 (PubMed)
  2. Phase I trial of pemetrexed plus oxaliplatin administered every other week in patients with metastatic cancer. Stover DG, Lockhart AC, Berlin JD, Chan E, Sandler AB, Sosman JA, Middlebrook V, Nicol S, Rothenberg ML (2008) Invest New Drugs 26(4): 339-45
    › Primary publication · 18463792 (PubMed)
  3. Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose. Chung CH, Mirakhur B, Chan E, Le QT, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TA (2008) N Engl J Med 358(11): 1109-17
    › Primary publication · 18337601 (PubMed) · PMC2361129 (PubMed Central)
  4. A phase I trial of irinotecan alternating with epirubicin in patients with advanced malignancies. Goff LW, Rothenberg ML, Lockhart AC, Roth BJ, VerMeulen WL, Chan E, Berlin JD (2008) Am J Clin Oncol 31(5): 413-6
    › Primary publication · 18838875 (PubMed)
  5. A phase I trial of CEP-701 + gemcitabine in patients with advanced adenocarcinoma of the pancreas. Chan E, Mulkerin D, Rothenberg M, Holen KD, Lockhart AC, Thomas J, Berlin J (2008) Invest New Drugs 26(3): 241-7
    › Primary publication · 18217204 (PubMed)
  6. Controversies in the adjuvant treatment of pancreas cancer: a lack of knowledge or simply a lack of will? Chan E, Berlin JD (2007) Gastrointest Cancer Res 1(5): 204-6
    › Primary publication · 19262710 (PubMed) · PMC2632532 (PubMed Central)